Showing results (1-10 of 194) with videos related to
Sort By:
Pageof 20
F1000Research|November 18, 2016
Current strategies to treat tuberculosisAnthony T Podany, Susan SwindellsAntiviral Therapy|January 7, 2015
Impact of an electronic medical record on the incidence of antiretroviral prescription errors and HIV pharmacist reconciliation on error correction among hospitalized HIV-infected patientsRishi Batra, Jane Wolbach-Lowes, Susan Swindells, et al.Open Forum Infectious Diseases|March 13, 2023
Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Patients With HIV-1 Infection and Ongoing Substance Use Disorder: The BASE StudyJoshua P Havens, Sara H Bares, Elizabeth Lyden, et al.The Journal of Antimicrobial Chemotherapy|September 23, 2016
Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patientsUriel Sandkovsky, Anthony T Podany, Courtney V Fletcher, et al.BMC Infectious Diseases|July 8, 2018
A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfactionSarah S Lee, Joshua P Havens, Harlan R Sayles, et al.AIDS (London, England)|January 16, 2018
Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamideAnthony T Podany, Sara H Bares, Joshua Havens, et al.Topics in Antiviral Medicine|June 16, 2018
New and Noteworthy in Tuberculosis Diagnostics and TreatmentSusan SwindellsClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 3, 2024
Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis PreventionAnthony T Podany, Yoninah Cramer, Marjorie Imperial, et al.Pharmacogenetics and Genomics|August 21, 2020
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapineDavid W Haas, Anthony T Podany, Yajing Bao, et al.Pageof 20